{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:42:08Z","timestamp":1776890528589,"version":"3.51.2"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Collaborative Research Center","award":["CRC1213"],"award-info":[{"award-number":["CRC1213"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In chronic thromboembolic pulmonary hypertension (CTEPH) impaired pulmonary hemodynamics lead to right heart failure. Natriuretic peptides reflect hemodynamic disease severity. Pregnancy-associated plasma protein-A (PAPP-A) might address another aspect of CTEPH - chronic tissue injury and inflammation. This study assessed dynamics of PAPP-A in CTEPH patients who undergo therapy with pulmonary endarterectomy (PEA) or balloon pulmonary angioplasty (BPA).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The study included a total of 125 CTEPH patients scheduled for treatment (55 PEA\/ 70 BPA) and a control group of 58 patients with pulmonary hypertension other than CTEPH. Biomarker measurement was performed at baseline and follow-up in the CTEPH cohort, prior to each BPA in the BPA cohort and once in the control group.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The median PAPP-A level was slightly higher (<jats:italic>p<\/jats:italic>\u2009=\u20090.05) in CTEPH patients [13.8 (11.0\u201318.6) mU\/L], than in the control group [12.6 (8.6\u201316.5) mU\/L], without a difference between the BPA and PEA group (<jats:italic>p<\/jats:italic>\u2009=\u20090.437) and without a correlation to mean pulmonary artery pressure (<jats:italic>p<\/jats:italic>\u2009=\u20090.188), pulmonary vascular resistance (<jats:italic>p<\/jats:italic>\u2009=\u20090.893), cardiac index (<jats:italic>p<\/jats:italic>\u2009=\u20090.821) and right atrial pressure (<jats:italic>p<\/jats:italic>\u2009=\u20090.596). PEA and BPA therapy decreased the mean pulmonary artery pressure (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and pulmonary vascular resistance (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and improved the WHO-functional-class (baseline: I:0\/II:25\/III:80\/IV:20 vs. follow-up: I:55\/II:58\/III:10\/IV:2). PAPP-A levels decreased after PEA [13.5 (9.5\u201317.5) vs. 11.3 (9.8\u201313.6) mU\/L; <jats:italic>p<\/jats:italic>\u2009=\u20090.003) and BPA treatment [14.3 (11.2\u201318.9) vs. 11.1 (9.7\u201313.3) mU\/L; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The decrease of PAPP-A levels is delayed in comparison to N-terminal pro-B-type natriuretic peptide.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>PAPP-A is overexpressed in CTEPH and decrease significantly after surgical or interventional therapy, however without association to hemodynamics. Further investigation is needed to define the underlying mechanism of PAPP-A expression and changes after therapy in CTEPH.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12931-020-01472-3","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T12:06:34Z","timestamp":1596456394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pregnancy-associated plasma protein A \u2013 a new indicator of pulmonary vascular remodeling in chronic thromboembolic pulmonary hypertension?"],"prefix":"10.1186","volume":"21","author":[{"given":"Steffen D.","family":"Kriechbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph B.","family":"Wiedenroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Mielzarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Guth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian W.","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckhard","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Liebetrau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-6491","authenticated-orcid":false,"given":"Till","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"issue":"xxxx","key":"1472_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijcard.2018.08.079","volume":"272","author":"H Wilkens","year":"2018","unstructured":"Wilkens H, Konstantinides S, Lang IM, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272(xxxx):69\u201378. https:\/\/doi.org\/10.1016\/j.ijcard.2018.08.079.","journal-title":"Int J Cardiol"},{"issue":"5","key":"1472_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.healun.2017.12.006","volume":"37","author":"SD Kriechbaum","year":"2018","unstructured":"Kriechbaum SD, Wiedenroth CB, Wolter J-SS, et al. N-terminal pro-B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2018;37(5):639\u201346. https:\/\/doi.org\/10.1016\/j.healun.2017.12.006.","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"1472_CR3","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1073\/pnas.96.6.3149","volume":"96","author":"JB Lawrence","year":"1999","unstructured":"Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A. 1999;96(6):3149\u201353. https:\/\/doi.org\/10.1073\/pnas.96.6.3149.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1472_CR4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cardfail.2011.05.011","volume":"17","author":"A Funayama","year":"2011","unstructured":"Funayama A, Shishido T, Netsu S, et al. Serum pregnancy-associated plasma protein A in patients with heart failure. J Card Fail. 2011;17(10):819\u201326. https:\/\/doi.org\/10.1016\/j.cardfail.2011.05.011.","journal-title":"J Card Fail"},{"issue":"3","key":"1472_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.tem.2013.12.002","volume":"25","author":"R Troncoso","year":"2014","unstructured":"Troncoso R, Ibarra C, Vicencio JM, Jaimovich E, Lavandero S. New insights into IGF-1 signaling in the heart. Trends Endocrinol Metab. 2014;25(3):128\u201337. https:\/\/doi.org\/10.1016\/j.tem.2013.12.002.","journal-title":"Trends Endocrinol Metab"},{"key":"1472_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000341745","volume":"23","author":"R Pf\u00e4ffle","year":"2012","unstructured":"Pf\u00e4ffle R, Kiess W, Klammt J. Downstream insulin-like growth factor. Endocr Dev. 2012;23:42\u201351. https:\/\/doi.org\/10.1159\/000341745.","journal-title":"Endocr Dev"},{"key":"1472_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.vph.2015.04.005","volume":"73","author":"Q Yang","year":"2015","unstructured":"Yang Q, Sun M, Ramchandran R, Raj JU. IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: role of epigenetic regulation. Vasc Pharmacol. 2015;73:20\u201331. https:\/\/doi.org\/10.1016\/j.vph.2015.04.005.","journal-title":"Vasc Pharmacol"},{"issue":"6","key":"1472_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1165\/rcmb.2015-0388OC","volume":"55","author":"M Sun","year":"2016","unstructured":"Sun M, Ramchandran R, Chen J, Yang Q, Raj JU. Smooth muscle insulin-like growth factor-1 mediates hypoxia-induced pulmonary hypertension in neonatal mice. Am J Respir Cell Mol Biol. 2016;55(6):779\u201391. https:\/\/doi.org\/10.1165\/rcmb.2015-0388OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"12","key":"1472_CR9","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1161\/CIRCRESAHA.106.146183","volume":"100","author":"SC Harrington","year":"2007","unstructured":"Harrington SC, Simari RD, Conover CA. Genetic deletion of pregnancy-associated plasma protein-A is associated with resistance to atherosclerotic lesion development in apolipoprotein E-deficient mice challenged with a high-fat diet. Circ Res. 2007;100(12):1696\u2013702. https:\/\/doi.org\/10.1161\/CIRCRESAHA.106.146183.","journal-title":"Circ Res"},{"issue":"4","key":"1472_CR10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1158\/1535-7163.MCT-14-0880","volume":"14","author":"MA Becker","year":"2015","unstructured":"Becker MA, Haluska P, Bale LK, Oxvig C, Conover CA. A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts. Mol Cancer Ther. 2015;14(4):973\u201381. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0880.","journal-title":"Mol Cancer Ther"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01472-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-020-01472-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01472-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T23:49:28Z","timestamp":1627948168000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-01472-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-01472-3","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics committee of the Facility of Medicine of the Justus-Liebig-University in Giessen, Germany in July of 2014 (referral numbers 43\/14 and 44\/14). All participating patients were comprehensively informed by a physician and gave written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants gave written informed consent to be included in the study. This manuscript does not include any individual person\u2019s data in any form, including individual details, images or videos. Therefore, no dedicated consent for publication is needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CBW received consultant honoraria and\/or speaker fees from Actelion, Bayer AG, MSD, Pfizer and BTG; CWH received lecture or consulting honoraria from BRAHMS\/ Thermo Fisher; EM received lecture or consulting honoraria from Actelion, Bayer, MSD, GSK, Pfizer and MSD; CL received lecture or consulting honoraria from Abbott, Astra Zeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Daiichi-Sankyo and Pfizer-Bristol-Myers Squibb. TK received speaker fees from Abbott and Brahms; SDK, FR and LM have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}